---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-047036"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:39:32.987300+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KalVista reports Q1 FY2024 net loss $25.3M; KONFIDENT phase 3 enrollment achieved

## Summary
- Net loss $25.3M ($0.74/share) vs $23.0M ($0.94/share) in prior-year quarter.
- Cash, equivalents and marketable securities $123.3M vs $149.4M as of April 30, 2023.
- Phase 3 KONFIDENT trial for sebetralstat hit enrollment target of 114 patients; data readout on track for Q4 2023.
- NDA submission planned for H1 2024; Nicole Sweeny appointed Chief Commercial Officer.

## SEC filing metadata
- accession: 0000950170-23-047036
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/0000950170-23-047036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/kalv-20230907.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-047036
- JSON: https://secwatch.observer/filing/0000950170-23-047036.json
- Plain text: https://secwatch.observer/filing/0000950170-23-047036.txt

## Key facts
- Earnings Releases
  KalVista Pharmaceuticals, Inc. reported the first fiscal quarter ended July 31, 2023 results: net income $25.3 million, or $(0.74) per weighted average basic and diluted share, EPS $(0.74) per weighted average basic and diluted share.
  - Period: the first fiscal quarter ended July 31, 2023
  - Net income: $25.3 million, or $(0.74) per weighted average basic and diluted share
  - EPS: $(0.74) per weighted average basic and diluted share
  - Result: reported results
  source text: KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/0000950170-23-047036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.